Recursion Pharmaceuticals (NASDAQ: RXRX) net income
Recursion Pharmaceuticals reported a net loss of $644.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $463.7m. Earnings per share were −$1.44.
Recursion Pharmaceuticals's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$644.8m | — | −863.4% | −$1.44 |
| 2024 | −$463.7m | — | −788.0% | −$1.69 |
| 2023 | −$328.1m | — | −736.0% | −$1.58 |
| 2022 | −$239.5m | — | −601.0% | −$1.36 |
| 2021 | −$186.5m | — | −1,832.2% | −$1.49 |
| 2020 | −$87.0m | — | −2,196.0% | −$3.99 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Recursion Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Recursion Pharmaceuticals ranks 482nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Recursion Pharmaceuticals, −863.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 480th | Crispr Therapeutics AG | −$581.6m | −16,569.8% |
| 481st | Dentsply Sirona | −$598.0m | −16.3% |
| 482nd | Recursion Pharmaceuticals | −$644.8m | −863.4% |
| 483rd | Vor Biopharma | −$696.0m | — |
| 484th | Sarepta Therapeutics | −$713.4m | −32.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Recursion Pharmaceuticals
- How much did Recursion Pharmaceuticals earn in fiscal 2025?
- Recursion Pharmaceuticals reported a net loss of $644.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $463.7m.
- What are the earnings per share of Recursion Pharmaceuticals?
- They were −$1.44 in fiscal 2025, compared with −$1.69 in fiscal 2024.
- Where does Recursion Pharmaceuticals rank in its sector by net income?
- It ranks 482nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Recursion Pharmaceuticals come from?
- From the annual report (Form 10-K) that Recursion Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Recursion Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Recursion Pharmaceuticals: the Recursion Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.